The addition of ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, topline data showed.
Updated OS results of the phase 3 MONALEESA-3 study, scheduled for presentation during ESMO Breast Cancer Congress, included median follow-up of 5 years among women who received ribociclib (Kisqali, Novartis) plus fulvestrant vs. fulvestrant alone in the first-line setting, according to a Novartis press release.
Previous results presented during the 2019 ESMO Congress